Autism is Eradicated in 15% of Cases with GcMAF in a trial of 1,500 Children

Over the last two years, four doctors led by Dr Jeffrey Bradstreet have eradicated autism using GcMAF in 15% of children and improved 70%. Another 15% did not respond.

St Peter Port, Guernsey (April 3, 2013) — Yesterday, April 2, was World Autism Awareness Day. Over the last two years, four doctors led by Dr Jeffrey Bradstreet have eradicated autism using GcMAF in 15% of children and improved 70%. Another 15% did not respond.

GcMAF is a vital part of the human immune system that does not function without it. However, many viruses attempt to prevent production of the body’s own GcMAF. If successful, this collapses the immune system, resulting in the infections growing unchecked. Immuno Biotech extracts and isolates GcMAF molecules that can then be injected to restore the body’s level of GcMAF to normal so that it can fight infections naturally. The quality of Immuno Biotech’s GcMAF and their exhaustive testing has made it the World’s leading supplier and the provider of choice for doctors and scientists with the company being cited in eleven research papers to date.

David Noakes, Immuno Biotech’s CEO, explained, “Dr Bradstreet used the nagalase and other tests to prove that 85% of autistic children had high levels of viruses and a compromised immune system. He did a study of 1500 autistic children and gave them weekly injections of our GcMAF. 70% of the children responded to the treatment with reduced symptoms, and an another 15% made full recoveries. Further trials around the world are coming up with identical results. The reduction of autistic symptoms is permanent provided that GcMAF has been taken for long enough for the body to start to produce its own GcMAF at normal levels, typically 24 weeks, but first results are usually seen inside 8 weeks.”

Dr. Jeff Bradstreet MD is an internationally recognized researcher in autism (http://www.drbradstreet.org) and will be presenting his latest finding on the effects of GcMAF on autism at the world’s first GcMAF conference, which will be held on the 19th, 20th and 21st of April in Frankfurt, Germany. Presentations by leading scientists and doctors from around the world will report on their exceptional results with case histories. Details can be found at http://gcmafconference.org/. Currently there are over 60 research papers on GcMAF by 142 eminent scientists with new peer-reviewed papers being added at an increasing rate from university teams and doctors from dozens of countries. Many of the independent research papers on GcMAF are listed on http://www.gcmaf.eu.

Background
A weekly injection of a tiny clear drop restores the level of GcMAF to normal, effectively one millionth of a blood transfusion. That enables the body’s own immune system to fight the disease, with the only occasional side effects being mild, cold-like symptoms as the immune system wakes up. The time it takes to fight the infection and return to producing normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel: 0044 7781 411737, Web: http://www.gcmaf.eu and click “contact” at the top to email.